• 0 Bewertung(en) - 0 im Durchschnitt
  • 1
  • 2
  • 3
  • 4
  • 5
GAVI/CEPI - Impfallianzen COVID 19
CEPI publishes analysis of COVID-19 vaccine development landscape
Research by CEPI’s vaccine R&D team, published in Nature Reviews Drug Discovery, has identified 115 COVID-19 vaccines in development.
The CEPI team have been continuously maintaining an overview of the global landscape of COVID-19 vaccine development activity.
From February, 2020, onwards, the team studied the landscape of COVID-19 vaccine candidates by using internal and external data sources, including vaccine development programmes reported through the WHO’s authoritative and continually updated list; information from calls for proposals and direct communications with vaccine developers and partners; clinical trial and funders databases, publicly available literature; and media and press releases.
The authors of this paper stressed that strong international coordination and co-operation among vaccine developers, regulators, policymakers, funders, public health bodies and governments will be needed to ensure safe and effective vaccine can be manufactured in sufficient quantities and made globally accessible.
They also highlighted that CEPI maintains a dynamic approach to the management of its vaccine portfolio and is committed to making its enabling science resources available globally.
Finally, the authors urged the global vaccine community to collectively mobilise the technical and financial support needed to successfully address the COVID-19 pandemic through a global vaccination programme. Earlier this year, CEPI published an estimate that $2 billion would be required to develop a vaccine against COVID-19.

Strong international coordination and co-operation
CEPI establishes Representative Office in Shanghai, China
CEPI, the Coalition for Epidemic Preparedness Innovations, has officially announced the legal establishment of a Representative Office in Shanghai, China. Through its Shanghai Representative Office, CEPI will seek cooperation with China in the prevention and control of pandemic diseases, including funding of public health research projects, research and development of vaccines, and international scientific, technology and development cooperation and exchanges.

CEPI is a global organisation, working on global solutions to global issues. We already have offices in Oslo, London and Washington D.C., and I am pleased that we can now add the CEPI Shanghai Representative Office to that list. The CEPI Shanghai Representative Office will facilitate our collaboration with China, and we look forward to working closely with Chinese partners in the fight against COVID-19
Dr. Richard Hatchett
Chief Executive Officer, CEPI

We welcome the establishment of the Representative Office of CEPI in Shanghai, which is of great significance to the promotion of international scientific and technological cooperation and exchanges between Shanghai and the world in the field of epidemic prevention and innovation. We will actively promote practical and efficient cooperation between CEPI and relevant research institutions to make contributions to the fight against COVID-19
Mr. Quan Zhang
Chairman of STCSM...............
CEPI launches new funding opportunity to accelerate COVID-19 vaccine development and production
  • CEPI launches a new Call for Proposals to accelerate COVID-19 vaccine development and production.
  • Focus for funding will be on vaccine candidates that have the potential to be developed rapidly and manufactured globally at scale.
  • New call will allow CEPI to expand its existing portfolio to increase chances of success.
OSLO, NORWAY. 5 MAY 2020 – CEPI, the Coalition for Epidemic Preparedness Innovations, is today issuing a new Call for Proposals inviting organizations around the world to apply for funding to speed up development, scale-up manufacturing capacity, and expand the geographical footprint of production of COVID-19 vaccine candidates.
The Call for Proposals will be open until at least 30 June 2020 with applications reviewed on a rolling basis every two weeks. It will support the rapid development of vaccines which could be available for licensure in 12-18 months or less, and increase the availability of vaccines for wide-spread global deployment.
Billions of doses of vaccine are needed as soon as possible to bring the pandemic to an end around the world, so this Call has a particular emphasis on vaccine manufacturing capacity and the capabilities to deliver global development plans. Applicants will be required to demonstrate both their ability to rapidly develop their vaccine candidate, as well as manufacture it at scale.
Since January 2020 CEPI has acted at pace to establish a COVID-19 vaccine development portfolio comprising nine promising vaccine candidates, three of which are already in clinical testing. In parallel we have been closely monitoring the global vaccine development landscape with a view to enlarging our portfolio as and when resourcing allows.
Following last week’s launch of the landmark ACT Accelerator and in line with CEPI’s strategy to continually seek to build a portfolio with the best chance of success, CEPI is seeking to expand and diversify its portfolio. By supporting a broad and balanced portfolio, including a range of vaccine technologies and geographical manufacturing locations, CEPI is seeking to maximize the likelihood of rapidly delivering safe, effective and globally accessible vaccines against COVID-19............

Gehe zu:

Benutzer, die gerade dieses Thema anschauen: 1 Gast/Gäste